The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
Discover how Mounjaro the revolutionary weight-loss and diabetes drug by Eli Lilly is set to transform obesity management in ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...
The FDA declared the tirzepatide shortage over in October 2023, but a lawsuit by Outsourcing Facilities Association, a trade ...